

Prof. Dr.

Huu Phuc Nguyen

Department of Human Genetics (W3)

Male, born 23.06.1976, German Nationality

Faculty of Medicine

44801 Bochum, Germany

Mail: Huu.Nguyen-r7w@rub.de

Website: www.ruhr-uni-bochum.de/mhg/



Academic Education

1996-2003 Studies in Medicine (Medical School of Hannover, Germany),

Academic Degrees

2005 Doctorate: Dr. med., University of Tuebingen

Career

2000-2001 Research fellow at Department of Human Genetics, Emory University, Atlanta, USA

2003-2009 Resident in Clinical Genetics, Department of Medical Genetics and Neuropediatrics, University Clinics of Tuebingen

2005-2018 Group leader Huntington Disease, Department of Medical Genetics, University of Tuebingen

5/2009 Board Certified for Clinical Genetics (Facharzt)

2012-2018 Consultant Physician, Institute of Medical Genetics and Applied Genomics, University of Tuebingen

2016-2018 Associate Director, Institute of Medical Genetics and Applied Genomics, University of Tuebingen

1/2019- W3 Professor, Department of Human Genetics, Ruhr University Bochum, Bochum, Germany

Others (selected)

2000-2001 Scholarship from DAAD for research stay at Emory University, Atlanta, USA

2005 Young Investigator Award World Congress on HD in Manchester

2006 Research Award from TSE Systems

2007 Carl-Liebermeister Award

2010 First Poster prize winner at the CHDI HD Therapeutics conference

2012-2016 Coordinator of the European Industrial Doctorate Network "PhenoRat" (EU FP7)

2013-2017 Coordinator of the European Research Project "SWITCH-HD" (EU FP7)

2018-2023 Coordinator of the European Research Project "TreatPolyQ" (E-rare)

2024- Coordinator of the European Research Project "deICAA-HD" (JPND)

10 selected publications

1. Weber JJ, Anger SC, Pereira Sena P, Incebacak Eltemur RD, Huridou C, Fath F, Gross C, Casadei N, Riess O, **Nguyen HP**. Calpains as novel players in the molecular pathogenesis of spinocerebellar ataxia type 17. *Cell Mol Life Sci* 79: 262 (2022).
2. Hakim-Eshed V, Boulos A, Cohen-Rosenzweig C, Yu-Taeger L, Ziv T, Kwon YT, Riess O, **Nguyen HHP**, Ziv NE, Ciechanover A. Site-specific ubiquitination of pathogenic huntingtin attenuates its deleterious effects. *Proc Natl Acad Sci U S A*.117(31):18661-18669. doi: 10.1073/pnas.2007667117 (2020).
3. Weber JJ, Golla M, Guaitoli G, Wanichawan P, Hayer SN, Hauser S, Krahl AC, Nagel M, Samer S, Aronica E, Carlson CR, Schöls L, Riess O, Gloeckner CJ, **Nguyen HP**, Hübener-Schmid J. A combinatorial approach to identify calpain cleavage sites in the Machado-Joseph disease protein ataxin-3. *Brain*. 140(5):1280-1299 (2017).
4. Clemens LE, Weber JJ, Wlodkowski, Yu-Taeger L, Michaud M, Calaminus C, Eckert SH, Gaca J, Weiss A, Magg JCD, Jansson EKH, Eckert GP, Pichler BJ, Bordet T, Pruss RM, Riess O, **Nguyen HP**. Olesoxime suppresses calpain activation and mutant huntingtin fragmentation in the BACHD rat, *Brain* 138(Pt 12):3632-53 (2015).
5. Eckmann J*, Clemens LE*, Eckert SH, Hagl S, Yu-Taeger L, Bordet T, Pruss RM, Muller WE, Leuner K, **Nguyen HP***, Eckert GP*. Mitochondrial Membrane Fluidity is Consistently Increased in Different Models of Huntington Disease: Restorative Effects of Olesoxime. *Mol Neurobiol*. 50(1):107-18 (2014). (*equal contribution)
6. Kelp A, Koeppen AH, Petrasch-Parwez E, Calaminus C, Bauer C, Portal E, Yu-Taeger L, Pichler B, Bauer P, Riess O, **Nguyen HP**. A novel transgenic rat model for spinocerebellar ataxia type 17 recapitulates neuropathological changes and supplies in vivo imaging biomarkers. *J Neurosci*. 33(21):9068-81 (2013).
7. Hübener J, Weber JJ, Richter C, Honold L, Weiss A, Murad F, Breuer P, Wüllner U, Bellstedt P, Paquet-Durand F, Takano J, Saido TC, Riess O, **Nguyen HP**. Calpain mediated ataxin-3 cleavage in the molecular pathogenesis of Spinocerebellar Ataxia Type 3 (SCA3). *Hum Mol Genet*. 22(3):508-18 (2013).
8. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, **Nguyen HP**. A Novel BACHD Transgenic Rat Exhibits Characteristic Neuropathological Features of Huntington Disease. *J Neurosci*. 32 (44) :15426-15438 (2012).
9. Metzger S, Saukko M, Van Che H, Tong L, Puder Y, Riess O, **Nguyen HP**. Age at onset in Huntington's disease is modified by the autophagy pathway: implication of the V471A polymorphism in Atg7. *Hum Genet*. 128 (4) :453-9 (2010).
10. **Nguyen HP**, Kobbe P, Rahne H, Wörpel T, Jäger B, Stephan M, Pabst R, Holzmann C, Riess O, Korr H, Kántor O, Petrasch-Parwez E, Wetzler R, Osmand A, von Hörsten S. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. *Hum Mol Genet* 15 (21) :3177-94 (2006).